Oklo stock tumbles as Financial Times scrutinizes valuation
MENLO PARK, Calif. - Sight Sciences, Inc. (NASDAQ:SGHT), a medical device company with a market capitalization of $183 million and an impressive gross profit margin of 85%, announced Wednesday that a systematic review and meta-analysis published in the European Journal of Ophthalmology has demonstrated positive long-term outcomes for its OMNI Surgical System in treating open-angle glaucoma. According to InvestingPro analysis, the company currently appears undervalued based on its Fair Value metrics.
The meta-analysis, which included 29 publications based on 22 unique studies involving 2,379 eyes, found that approximately 89% of patients achieved treatment success, defined as intraocular pressure (IOP) reduction of at least 20% from baseline, after 6, 12, and 24 months. While the clinical results are promising, InvestingPro data shows that analysts maintain a moderate buy consensus with price targets ranging from $4 to $5 per share. InvestingPro subscribers have access to 8 additional key insights about SGHT’s investment potential.
According to the study, the OMNI system, which enables implant-free minimally invasive glaucoma surgery, significantly reduced IOP with mean measurements below 18 mmHg at 12 months when used in combination with cataract surgery. This trend continued at 24 months.
The analysis also showed that 66-68% of patients remained medication-free after 6 and 12 months. Average IOP-lowering medication use decreased from a range of 0.9-3.4 medications at baseline to 0.1-2.2 medications at month 12.
"The favorable safety and efficacy profile demonstrated in our meta-analysis reinforces how OMNI is a beneficial treatment option for patients with primary open-angle glaucoma," said Obeda Kailani, consultant ophthalmologist at King’s College Hospital, London, and lead study author.
The findings were presented at the European Society of Cataract & Refractive Surgeons meeting in Copenhagen on Monday.
The meta-analysis also included economic analyses indicating OMNI is cost-effective compared to iStent inject, with slightly higher quality-adjusted life years attributed to OMNI’s favorable adverse event profile.
Paul Badawi, Co-Founder and CEO of Sight Sciences, stated that the meta-analysis is part of the company’s commitment to generate strong clinical evidence demonstrating the safety, effectiveness, and durability of OMNI.
The information in this article is based on a press release statement from Sight Sciences.
In other recent news, Sight Sciences Inc. reported its second-quarter 2025 earnings, surpassing revenue expectations with $19.6 million, compared to the forecasted $18.18 million. The company also posted a narrower-than-expected loss per share of $0.23, beating the anticipated loss of $0.26. Following these results, Sight Sciences raised its 2025 revenue guidance, indicating confidence in its financial outlook. Lake Street Capital Markets responded by upgrading Sight Sciences from Hold to Buy, setting a price target of $5.00. This upgrade was attributed to the company’s stabilizing business and stronger-than-expected financial performance. Additionally, UnitedHealthcare announced that it will begin covering Sight Sciences’ OMNI Surgical System for glaucoma procedures starting October 1, 2025. This policy update will include coverage for several minimally invasive procedures for adults with mild to moderate open-angle glaucoma. These developments reflect recent positive momentum for Sight Sciences in both its financial performance and market reach.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.